Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Centene Corp (CNC) vs Incyte Corporation (INCY) Price & Performance

Centene CorpTrade
Incyte CorporationTrade

Price performance (Past 24H)

Key statistics

Centene Corp vs Incyte Corporation — how do they compare? Centene Corp trades at $66.79 (market cap $32.05B), while Incyte Corporation trades at $120.67 (market cap $24.54B). The key difference: Centene Corp is the larger of the two by market cap, and Centene Corp is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.

CNCINCY
Market Cap
$32.05B$24.54B
Sector
HealthHealth
52-Week High
$68.72$129.93
52-Week Low
$26.17$81.61
Enterprise Value
$21.10B$20.04B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Centene Corp

Centene (CNC) trades at $66.94, up 0.57% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat estimates with EPS of $2.51 versus $1.09 expected, driven by margin recovery and cost control. The stock shows attractive valuation metrics, including a P/E of 8.06 and P/S of 0.16, while revenue growth remains robust at $194.78B in 2025.

Outlook is positive with a consensus price target of $71.00, though risks include Medicaid membership volatility and net income margin pressure. The company's raised 2026 EPS guidance and operational cash flow strength support upside potential, but investors should weigh competitive and regulatory challenges in the managed care sector.

Incyte Corporation

Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.

Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Centene Corp

Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.

Read more on CNC

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY